| Autor: |
Plate JM; Division of Oncology and Hematology, Department of Immunology/Microbiology, Rush University Medical Center, 1653 West Congress Parkway, Chicago, IL 60612, USA. jplate@rush.edu |
| Jazyk: |
angličtina |
| Zdroj: |
Surgical oncology clinics of North America [Surg Oncol Clin N Am] 2007 Oct; Vol. 16 (4), pp. 919-43, xi. |
| DOI: |
10.1016/j.soc.2007.07.012 |
| Abstrakt: |
The immune systems of patients with newly diagnosed pancreatic cancers are functional, with T-cell responses capable of responding to tumor antigen presentation. Pancreatic tumors have been demonstrated to express tumor antigens as mutated, altered, underglycosylated and/or inappropriately overexpressed proteins. Considering these two facts, it should be possible for patients' bodies to recognize their tumors as foreign and to reject them. A number of clinical trials have been initiated to exploit this immune activation to eradicate or stabilize tumor growth. Immunotherapeutic trials include the specific testing of a variety of tumor vaccines, of cytokines as adjuvants or directed cytotoxicity, and of monoclonal antibodies to target specific molecules. This article reviews evidence for immune-cell activation and function in patients with pancreatic cancer, and evidence that pancreatic tumor cells express tumor antigens, or mutated (or altered) proteins. Nevertheless, tumors survive immune attacks by producing products that help them to circumvent effector T cells. The article thus examines complications of immune evasion by cancer cells, as well as the challenges of trying to exploit the immune system in solid tumors where tumor cell products can turn off invading immune T cells set to kill them. Finally, the article discusses the choices of a variety of clinical trials using immune modulation for patients with pancreatic cancer. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
